NeuBase Therapeutics to Present at Upcoming Investor Conferences in May 2020

Rhea-AI Summary

NeuBase Therapeutics, Inc. (NASDAQ: NBSE) announced participation in two significant virtual events. CEO Dietrich Stephan will engage in a fireside chat at the 6th Annual SunTrust Robinson Humphrey Life Sciences Summit on May 15 at 2:30 p.m. ET. Additionally, he will present a corporate overview at the RBC Capital Markets 2020 Global Healthcare Conference on May 20 at 1:20 p.m. ET. NeuBase focuses on innovative gene silencing therapies for rare genetic diseases, leveraging its proprietary PATrOL™ platform to enhance treatment options.

6th Annual SunTrust Robinson Humphrey Life Sciences Summit Virtual Series Fireside Chat
at 2:30 p.m. ET on May 15^TH

RBC Capital Markets 2020 Global Healthcare Conference presentation
at 1:20 p.m. ET on May 20^TH

PITTSBURGH, May 11, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced today that Dietrich Stephan, Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the 6th Annual SunTrust Robinson Humphrey Life Sciences Summit Virtual Series, as well as present a corporate overview and business update at the RBC Capital Markets 2020 Global Healthcare Conference, which are both being held in May 2020.

100%; border-collapse:collapse !important;">

Conferences Details:
8%; width:8%; min-width:8%;">Event:	92%; width:92%; min-width:92%;">6th Annual SunTrust Robinson Humphrey Life Sciences Summit Virtual Series
Format:	Fireside Chat
Date:	Friday, May 15TH
Time:	2:30 p.m. ET
Event:	RBC Capital Markets 2020 Global Healthcare Conference – Virtual Format
Format:	Presentation
Date:	Wednesday, May 20TH
Time:	1:20 p.m. ET
Location:	Webcast Link -  or at the company’s website (click here)

About NeuBase Therapeutics
NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL™ technology, NeuBase aims to first tackle rare, genetic diseases.

NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 430-7576

NeuBase Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
cait@lifescipublicrelations.com
OP: (646) 751-4366

FAQ

What is NeuBase Therapeutics participating in on May 15, 2020?

NeuBase Therapeutics will participate in a fireside chat at the 6th Annual SunTrust Robinson Humphrey Life Sciences Summit at 2:30 p.m. ET.

When is NeuBase's presentation at the RBC Capital Markets 2020 Global Healthcare Conference?

NeuBase's presentation at the RBC Capital Markets 2020 Global Healthcare Conference is scheduled for May 20, 2020, at 1:20 p.m. ET.

What is the focus of NeuBase Therapeutics?

NeuBase Therapeutics focuses on developing gene silencing therapies for rare genetic diseases using its innovative PATrOL™ platform.

What is the stock symbol for NeuBase Therapeutics?

The stock symbol for NeuBase Therapeutics is NBSE.